{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:08Z","timestamp":1791219368539,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014208","name":"People's Government of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["ZYQR201912118"],"award-info":[{"award-number":["ZYQR201912118"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["231111313300"],"award-info":[{"award-number":["231111313300"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107743","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:47:52Z","timestamp":1780710472000},"page":"107743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)"],"prefix":"10.1016","volume":"11","author":[{"given":"H.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-1077","authenticated-orcid":false,"given":"Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.107743_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107743_bib2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2026.107743_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107743_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.annonc.2025.09.140","article-title":"The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study","volume":"37","author":"Zheng","year":"2026","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107743_bib5","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107743_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107743_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/neuonc\/noaf025","article-title":"Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)","volume":"27","author":"Fan","year":"2025","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107743_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"Ozair","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107743_bib9","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107743_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","article-title":"Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107743_bib11","doi-asserted-by":"crossref","first-page":"e1869","DOI":"10.1634\/theoncologist.2020-0640","article-title":"Erlotinib for non-small cell lung cancer with leptomeningeal metastases: a phase II study (LOGIK1101)","volume":"25","author":"Nosaki","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107743_bib12","first-page":"4177","article-title":"Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107743_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107743_bib14","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.18632\/oncotarget.2886","article-title":"A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Jackman","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107743_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.107743_bib16","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107743_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107743_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2024.02.001","article-title":"A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis","volume":"25","author":"Wu","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107743_bib19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1759-7714.13738","article-title":"Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial","volume":"12","author":"Lu","year":"2021","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107743_bib20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107743_bib21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","article-title":"Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours","volume":"11","author":"Beauchesne","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107743_bib22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ijc.35460","article-title":"Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: a retrospective cohort study","volume":"157","author":"Xie","year":"2025","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107743_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1186\/s12885-025-14337-z","article-title":"High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.107743_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102500","article-title":"High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: a retrospective study","volume":"61","author":"Pan","year":"2025","journal-title":"Transl Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107743_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107743_bib26","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107743_bib27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"27","key":"10.1016\/j.esmoop.2026.107743_bib28","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107743_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pccm.2022.10.001","article-title":"Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors","volume":"1","author":"Sun","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107743_bib30","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.32604\/or.2025.064237","article-title":"Intrathecal pemetrexed administration and myelosuppression in patients with leptomeningeal metastases from lung adenocarcinoma: a retrospective study","volume":"33","author":"Chen","year":"2025","journal-title":"Oncol Res"},{"key":"10.1016\/j.esmoop.2026.107743_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","volume":"205","author":"Xie","year":"2025","journal-title":"Lung Cancer"},{"issue":"11 suppl","key":"10.1016\/j.esmoop.2026.107743_bib32","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107743_bib33","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3892\/ol.2016.4783","article-title":"Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol Lett"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:26:45Z","timestamp":1783178805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926016856"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107743","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107743"}}